[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mrna-vaccination\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mrna-vaccination":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100619184","sars-cov-2-mrna-vaccination-in-patients-with-hepatocellular-carcinoma-treated-with-immune-checkpoint-inhibitors-100619184",false,"NCT07341321","SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors","SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors (CoVaCheck) A Multicenter Retrospective Cohort Analysis in Austria","CoVaCheck","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Radiologically or histologically confirmed hepatocellular carcinoma\n* Treatment with immune checkpoint inhibitor-based therapy (mono- or combination therapy; e.g., atezolizumab\u002Fbevacizumab, durvalumab\u002Ftremelimumab, nivolumab, pembrolizumab)\n* Complete electronic medical records available\n* At least one imaging-based response assessment using mRECIST\n\nExclusion Criteria:\n\n* Missing key clinical data required for main analyses (e.g. survival status, date of progression, Child-Pugh class, BCLC stage)","ALL",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","A multicenter retrospective cohort analysis in Austria\n\nPrimary Objective:\n\nTo assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall response (mRECIST) in HCC (hepatocellular carcinoma).\n\nSecondary Objectives:\n\nEvaluate whether vaccination within 1 or 3 months affects OS (overall survival) , PFS (Progression free survival)), or TTP (Time to progression); compare outcomes by vaccination status, vaccine type, and prior infection; explore modification by cirrhosis severity and tumor characteristics; and assess safety (irAEs, steroid use, toxicity-related discontinuation).",[24,25,26],"mRNA Vaccination","Hepatocellular Carcinoma","Checkpoint Inhibitor",[28,29,30,31],"hepatocellular carcinoma","mRNA vaccination","response","immune checkpoint inhibitor","NOT_YET_RECRUITING","2026-01-07",{"date":35,"type":36},"2026-01-14","ACTUAL",{"date":38,"type":20},"2026-01",{"date":40,"type":20},"2026-12",{"name":42,"class":43},"Medical University of Graz","OTHER",5]